36.58 -0.19 (-0.52%)
After hours: 7:23PM EDT
|Bid||36.56 x 1300|
|Ask||36.78 x 1300|
|Day's Range||36.22 - 36.78|
|52 Week Range||33.97 - 46.47|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||16.99|
|Forward Dividend & Yield||1.44 (3.95%)|
|1y Target Est||N/A|
OPKO Health Inc. (OPK) and Pfizer Inc. (PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.
LOS ANGELES , Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca ...
–Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study–
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS) and Pfizer Inc. (PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. “AKCEA-ANGPTL3-LRx has the potential to treat people suffering from certain cardiovascular and metabolic diseases.
- Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New England Journal of Medicine –
Pfizer Inc. and LabCentral announced that Pfizer has selected Neutrolis and Mediar Therapeutics are the winners of this year’s Pfizer Golden Ticket Program. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups located in the heart of Cambridge, MA and proximate to Pfizer’s Kendall Square site.
Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has unanimously elected Pfizer’s Chief Executive Officer (CEO), Dr. Albert Bourla, to succeed him as Chairman of the Board of Directors effective January 1, 2020. Bourla will also retain the CEO role. Ian Read joined Pfizer in 1978.
Pfizer Inc. (PFE) announced today positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherapy trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program (B7451013, or JADE MONO-2). Pfizer announced positive top-line results from the first trial in the JADE program (B7451012, or JADE MONO-1) on May 15, 2019.
The Board of Directors of Pfizer Inc. today declared a 36-cent fourth-quarter 2019 dividend on the company’s common stock, payable December 2, 2019, to holders of the Common Stock of record at the close of business on November 8, 2019. Pfizer maintained the dividend from the third-quarter at 36 cents per share. The fourth-quarter 2019 cash dividend will be the 324th consecutive quarterly dividend paid by Pfizer.
First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials
Presentations of interest include a late-breaking abstract on expanded Phase 3 data in BRAF-mutant metastatic colorectal cancer
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2019 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Additionally, Pfizer Has Completed Enrollment of its Phase 3 Studies for its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Inv
TOKYO and NEW YORK, Aug. 21, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). XTANDI is currently indicated in the U.S. for the treatment of patients with castration-resistant prostate cancer (CRPC).
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.V. ("Mylan" or the "Company") (MYL) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (PFE). Under the terms of the agreement, Mylan shareholders will own a meager 43% of the combined company.
HERTFORDSHIRE, England and PITTSBURGH and NEW YORK, July 29, 2019 /PRNewswire/ -- Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company.